CA3165477A1 - Combinations - Google Patents
CombinationsInfo
- Publication number
- CA3165477A1 CA3165477A1 CA3165477A CA3165477A CA3165477A1 CA 3165477 A1 CA3165477 A1 CA 3165477A1 CA 3165477 A CA3165477 A CA 3165477A CA 3165477 A CA3165477 A CA 3165477A CA 3165477 A1 CA3165477 A1 CA 3165477A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- optionally substituted
- compound
- cooh
- co2h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952042P | 2019-12-20 | 2019-12-20 | |
| US62/952,042 | 2019-12-20 | ||
| US202063009754P | 2020-04-14 | 2020-04-14 | |
| US63/009,754 | 2020-04-14 | ||
| PCT/US2020/065411 WO2021127046A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3165477A1 true CA3165477A1 (en) | 2021-06-24 |
Family
ID=76478099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3165477A Pending CA3165477A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230042653A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069224A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023507799A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220119428A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115103673A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020408698A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012286A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165477A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294084A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007624A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202135810A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127046A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5411847B2 (ja) * | 2007-04-25 | 2014-02-12 | Msd株式会社 | Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| CA2706946A1 (en) * | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| HRP20140821T1 (hr) * | 2009-09-15 | 2014-10-10 | Merck Sharp & Dohme Corp. | Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona |
| SMT201700595T1 (it) * | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| AU2016344040B2 (en) * | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US11932650B2 (en) * | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| EP3712150B1 (en) * | 2017-11-01 | 2024-06-12 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Macrocyclic compound serving as wee1 inhibitor and applications thereof |
| JP2022543832A (ja) * | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
-
2020
- 2020-12-16 EP EP20901854.8A patent/EP4069224A4/en active Pending
- 2020-12-16 AU AU2020408698A patent/AU2020408698A1/en not_active Abandoned
- 2020-12-16 US US17/757,511 patent/US20230042653A1/en not_active Abandoned
- 2020-12-16 WO PCT/US2020/065411 patent/WO2021127046A1/en not_active Ceased
- 2020-12-16 CN CN202080095319.0A patent/CN115103673A/zh active Pending
- 2020-12-16 KR KR1020227024839A patent/KR20220119428A/ko not_active Ceased
- 2020-12-16 MX MX2022007624A patent/MX2022007624A/es unknown
- 2020-12-16 BR BR112022012286A patent/BR112022012286A2/pt not_active IP Right Cessation
- 2020-12-16 IL IL294084A patent/IL294084A/en unknown
- 2020-12-16 CA CA3165477A patent/CA3165477A1/en active Pending
- 2020-12-16 JP JP2022538229A patent/JP2023507799A/ja active Pending
- 2020-12-18 TW TW109145166A patent/TW202135810A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022012286A2 (pt) | 2022-08-30 |
| EP4069224A4 (en) | 2023-12-20 |
| US20230042653A1 (en) | 2023-02-09 |
| JP2023507799A (ja) | 2023-02-27 |
| MX2022007624A (es) | 2022-08-16 |
| TW202135810A (zh) | 2021-10-01 |
| CN115103673A (zh) | 2022-09-23 |
| IL294084A (en) | 2022-08-01 |
| KR20220119428A (ko) | 2022-08-29 |
| AU2020408698A1 (en) | 2022-07-14 |
| EP4069224A1 (en) | 2022-10-12 |
| WO2021127046A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3165382A1 (en) | Combinations | |
| JP7794448B2 (ja) | 組み合わせ | |
| WO2021127047A1 (en) | Combinations | |
| IL294094A (en) | conjunctions | |
| IL294084A (en) | conjunctions | |
| WO2021127042A1 (en) | Combinations | |
| CA3165341A1 (en) | Combinations | |
| CA3174700A1 (en) | Combinations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250825 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260129 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260330 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260616 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |